Cargando…

Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries

Background. Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naive patients. DAAs for HCV infection have similar mechanisms of action and chemical structures to antiretrovirals for human immunodeficiency virus (HIV) infectio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hill, Andrew, Khoo, Saye, Fortunak, Joe, Simmons, Bryony, Ford, Nathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Articles and Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952605/ https://www.ncbi.nlm.nih.gov/pubmed/24399087 http://dx.doi.org/10.1093/cid/ciu012

Ejemplares similares

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus
por: van de Ven, Nikolien, et al.
Publicado: (2015)

Minimum costs to manufacture new treatments for COVID-19
por: Hill, Andrew, et al.
Publicado: (2020)

Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?
por: Vitoria, Marco, et al.
Publicado: (2016)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
por: Hill, Andrew, et al.
Publicado: (2016)

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries
por: Hill, Andrew, et al.
Publicado: (2015)

Securing accelerated access to long‐acting injectable cabotegravir for HIV prevention in low‐ and middle‐income countries
por: Jenkins, Sarah Y., et al.
Publicado: (2023)

Prices of second-line antiretroviral treatment for middle-income countries inside versus outside sub-Saharan Africa
por: Simmons, Bryony, et al.
Publicado: (2014)

The Need for Higher Minimum Staffing Standards in U.S. Nursing Homes
por: Harrington, Charlene, et al.
Publicado: (2016)

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
por: Barber, Melissa J., et al.
Publicado: (2020)

Time to act for reappraising the educational system for universal access to opioid analgesics, for quality palliative care and cancer-related pain relief in East Asian countries
por: Sumitani, Masahiko
Publicado: (2021)

Meeting the Demands of the Affordable Care Act: Improving Access to Primary Care
por: McGough, Peter M., et al.
Publicado: (2017)

Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis
por: Jones, Christopher R., et al.
Publicado: (2019)

Determination of minimum inhibitory and minimum bactericidal concentrations of Brazilian strains of Leptospira spp. for streptomycin sulphate
por: Rocha, Bruno Ribeiro, et al.
Publicado: (2020)

Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response
por: Simmons, Bryony, et al.
Publicado: (2015)

Access to high cost medicines in Australia: ethical perspectives
por: Lu, Christine Y, et al.
Publicado: (2008)

Open Access Publishing of Textbooks and Guidelines for Otolaryngologists in Developing Countries
por: Fagan, Johannes J.
Publicado: (2019)

Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis
por: Simmons, Bryony, et al.
Publicado: (2016)

Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients
por: Al-Busafi, Said A., et al.
Publicado: (2017)

Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects
por: Mofenson, Lynne M, et al.
Publicado: (2019)

The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries
por: Mennini, Francesco S., et al.
Publicado: (2021)

Improving Access to Medicines in Low and Middle Income Countries: Corporate Responsibilities in Context
por: Leisinger, Klaus Michael, et al.
Publicado: (2012)

The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries
por: Hill, Andrew M, et al.
Publicado: (2017)

Challenges to implement minimum effective volume in regional anesthesia
por: Subramani, Sudhakar, et al.
Publicado: (2019)

Using strategic price negotiations to contain costs and expand access to medicines in China
por: Si, Lei, et al.
Publicado: (2020)

Minimum important difference is minimally important in sample size calculations
por: Wong, Hubert
Publicado: (2023)

Cost-effectiveness analysis for clinicians
por: Hill, Suzanne R
Publicado: (2012)

Cochrane corner: community-level interventions to increase access to food in low- and middle-income countries
por: Durão, Solange, et al.
Publicado: (2022)

The argument(s) for lowering the US minimum required content of apheresis platelet components
por: Benjamin, Richard J., et al.
Publicado: (2018)

The costs and benefits of diagnosis of ADHD: commentary on Holden et al.
por: Russell, Ginny, et al.
Publicado: (2014)

Antiviral Drugs for EBV
por: Pagano, Joseph S., et al.
Publicado: (2018)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

The Impact of Adherence to Minimum Health Standards in the Philippines during the COVID-19 pandemic
por: Buhat, Christian Alvin H.
Publicado: (2021)

Financing global health security: estimating the costs of pandemic preparedness in Global Fund eligible countries
por: Eaneff, Stephanie, et al.
Publicado: (2023)

Antiviral defense: interferons and beyond
por: Stetson, Daniel B., et al.
Publicado: (2006)

Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low‐ to high‐income settings: making sure no one is left behind
por: Grillon, Céline, et al.
Publicado: (2018)

Influenza vaccination may have only minimum or no effect on COVID-19 in the aged population
por: Yao, Lan, et al.
Publicado: (2022)

Common data elements and minimum data sets in cerebral palsy: Start small to grow big
por: Dieterich, Klaus
Publicado: (2022)

Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy
por: Girardin, François, et al.
Publicado: (2021)

Antiviral Therapy for the Next Influenza Pandemic
por: Hurt, Aeron C.
Publicado: (2019)

Commentary: A pandemic blueprint for planning your act and acting your plan
por: Kobsa, Serge, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1v39nhr4tu4fgdsov3ocm2kuri